Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice
- Registration Number
- NCT02255266
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This study is conducted in Europe. The aim of this study is to investigate Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in daily Practice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1788
Inclusion Criteria
- Subjects of age above 18 years as per Victoza® SmPC par.4.2 and 5.1 diagnosed with type 2 diabetes receiving the first prescription of liraglutide in 2011
Exclusion Criteria
- None. Available data from all eligible patients for each center, will be included
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description A liraglutide -
- Primary Outcome Measures
Name Time Method Frequency of patients achieving HbA1c reduction of at least 1%-point Week 0, week 52
- Secondary Outcome Measures
Name Time Method Frequency of patients achieving HbA1c reduction of at least 1%-point After 4 and 24 months of treatment Change in HbA1c (Glycosylated haemoglobin)) Week 0, week 104 Percentage of treatment discontinuation for any reason At 4, 12 and 24 months Changes in blood pressure and lipid profile Week 0, week 104 Change in body weight Week 0, week 104 Frequency of patients achieving HbA1c target (<=7%) After 4, 12 and 24 months Frequency of patients achieving a body weight reduction of at least 3% After 4, 12 and 24 months Frequency of patients achieving the composite endpoint consisting in: HbA1c reduction of at least 1%-point and body weight reduction of at least 3% After 4, 12 and 24 months
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇮🇹Rome, Italy